Description | BX517 is a potent and selective inhibitor of PDK1 that binds to the ATP binding pocket of the protein (IC50 = 6 nM). | ||||
---|---|---|---|---|---|
Targets |
| ||||
In vitro | BX-517 blocks activation of Akt in tumor cells[2]. | ||||
In vivo | BX517 has poor pharmaceutical properties including short half-life (0.4 h in rat), low metabolic stability, and poor solubility[2]. |